Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIAT
Ratios

GT Biopharma (GTBP) Long-Term Debt Issuances (2017 - 2021)

GT Biopharma (GTBP) has disclosed Long-Term Debt Issuances for 7 consecutive years, with $1.2 million as the latest value for Q1 2021.

  • On a quarterly basis, Long-Term Debt Issuances rose 502.5% to $1.2 million in Q1 2021 year-over-year; TTM through Dec 2021 was $1.2 million, a 90.38% decrease, with the full-year FY2021 number at $1.2 million, down 90.38% from a year prior.
  • Long-Term Debt Issuances was $1.2 million for Q1 2021 at GT Biopharma, down from $6.9 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $7.1 million in Q1 2018 to a low of $195000.0 in Q2 2017.
  • A 5-year average of $2.3 million and a median of $1.2 million in 2020 define the central range for Long-Term Debt Issuances.
  • Peak YoY movement for Long-Term Debt Issuances: crashed 85.09% in 2019, then surged 3337.0% in 2020.
  • GT Biopharma's Long-Term Debt Issuances stood at $4.9 million in 2017, then surged by 43.1% to $7.1 million in 2018, then tumbled by 97.17% to $200000.0 in 2019, then soared by 3337.0% to $6.9 million in 2020, then plummeted by 82.47% to $1.2 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Long-Term Debt Issuances are $1.2 million (Q1 2021), $6.9 million (Q4 2020), and $1.2 million (Q3 2020).